Various animal studies have shown that liposomal formulations have higher antitumor efficacies compared to non-liposomal vaccine systems [50–52].Liposomal vaccines with basic fibroblast growth factor(bFGF) and MPL adjuvant induced Th1 and tumor-specific antibody response immunity in a mouse model[19]. This evidence concerns the gene FGF2 and neoplasm.